Mindray Expands Its Cardiac Biomarker Portfolio by Introducing hs-cTnI and NT-proBNP Assays
2023-10-25
Cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Many guidelines recommend cTn and NT-proBNP as important biomarkers for suspected acute coronary syndrome (ACS) and heart failure patients, respectively. These biomarkers can be used for early disease screening, risk stratification, rapid diagnosis, and therapeutic monitoring, enabling physicians to make clinical decisions quickly.
Mindray's hs-cTnI and NT-proBNP assays, jointly developed by Mindray and HyTest, have been validated by Wuhan Asian Heart Hospital and the Hennepin Healthcare Research Institute, demonstrating outstanding performance.
Mindray hs-cTnI Assay: An ideal biomarker for myocardial injury
Scientific detection system
Mindray hs-cTnl assay is unsusceptible to proteases and can avoid cTnl terminal hydrolysis. The absence of endogenous antibodies interference improves the accuracy of test results, and Mindray hs-cTnl assay achieves a 93% detection rate in healthy individuals.
Excellent assay performance
Mindray hs-cTnl assay with high sensitivity, precision, and specificity meets the requirements of laboratory quality management and clinical guidelines.
Mindray hs-cTnI Assay: An ideal biomarker for heart failure
High precision
The total imprecision (CV) of Mindray NT-proBNP ≤5%.
Good quality control stability
Strong anti-interference capacity
Empowering Cardiovascular Diseases Care with Reliable Solutions
The introduction of hs-cTnI and NT-proBNP assays has enabled Mindray to provide a comprehensive menu of cardiac tests, covering six parameters, for reliable diagnosis and management of cardiovascular diseases (CVDs).
Leveraging the collaborative strengths of HyTest and Mindray, we remain committed to prioritizing fundamental research and utilizing advanced engineering techniques to modify raw materials. This dedication allows us to deliver even more dependable solutions, leading to improved patient outcomes in the realm of cardiovascular diseases and beyond.
References
[1]https://www.who.int/news-room/fact-sheets/detail/car diovascular-diseases-(cvds)
[2] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. Circulation, 2018,138(20): e618-e651. DOl: 10.1161/CIR. 0000000000000617.
[3] Byrne R A, Rossello X, Coughlan J J, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)[J]. European heart journal, 2023, 44(38): 3720-3826.
[4] Jun Min.The National Health and Family Planning Commission issues "Guidelines for the construction and management of chest pain centers (trial)"[N]. Chinese Medical News, 2017-11-12(6).
[5] Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. Chinese guidelines for the diagnosis and treatment of heart failure 2018 J]. Chinese Journal of Heart Failure and Cardiomyopathy, 2018,(4):196-225. DOl: 10.3760/cma.j.issn.2096-3076.2018.12.02.
[6] Natl Med J China, September 20, 2022, Vol.102, No.35
